Pulse Biosciences Competitors

Pulse Biosciences (NASDAQ:PLSE) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Pulse Biosciences and Inovio Pharmaceuticals, as provided by MarketBeat.com.

Pulse Biosciences currently has a consensus price target of $43.00, indicating a potential upside of 97.16%. Inovio Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 94.95%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Pulse Biosciences is more favorable than Inovio Pharmaceuticals.

Insider & Institutional Ownership

11.4% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 36.0% of Inovio Pharmaceuticals shares are owned by institutional investors. 49.8% of Pulse Biosciences shares are owned by insiders. Comparatively, 4.0% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Pulse Biosciences and Inovio Pharmaceuticals' net margins, return on equity and return on assets.

Volatility and Risk

Pulse Biosciences has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Valuation and Earnings

This table compares Pulse Biosciences and Inovio Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Pulse Biosciences has higher earnings, but lower revenue than Inovio Pharmaceuticals. Pulse Biosciences is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Inovio Pharmaceuticals beats Pulse Biosciences on 7 of the 13 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for GenMark Diagnostics and Pulse Biosciences, as provided by MarketBeat.com.

GenMark Diagnostics presently has a consensus target price of $22.0125, suggesting a potential downside of 8.24%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than GenMark Diagnostics.

Insider and Institutional Ownership

96.9% of GenMark Diagnostics shares are held by institutional investors. Comparatively, 11.4% of Pulse Biosciences shares are held by institutional investors. 3.3% of GenMark Diagnostics shares are held by insiders. Comparatively, 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares GenMark Diagnostics and Pulse Biosciences' net margins, return on equity and return on assets.

Volatility and Risk

GenMark Diagnostics has a beta of 3.02, indicating that its stock price is 202% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares GenMark Diagnostics and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Pulse Biosciences has lower revenue, but higher earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Pulse Biosciences beats GenMark Diagnostics on 7 of the 13 factors compared between the two stocks.

Silk Road Medical (NASDAQ:SILK) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Silk Road Medical and Pulse Biosciences, as provided by MarketBeat.com.

Silk Road Medical presently has a consensus target price of $61.75, suggesting a potential upside of 23.16%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Silk Road Medical.

Insider and Institutional Ownership

11.4% of Pulse Biosciences shares are held by institutional investors. 7.8% of Silk Road Medical shares are held by insiders. Comparatively, 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Silk Road Medical and Pulse Biosciences' net margins, return on equity and return on assets.

Volatility and Risk

Silk Road Medical has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares Silk Road Medical and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Pulse Biosciences has lower revenue, but higher earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Pulse Biosciences beats Silk Road Medical on 8 of the 12 factors compared between the two stocks.

Alphatec (NASDAQ:ATEC) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Alphatec and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Pulse Biosciences has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Alphatec and Pulse Biosciences, as provided by MarketBeat.com.

Alphatec presently has a consensus target price of $15.4286, suggesting a potential downside of 12.34%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Alphatec.

Insider and Institutional Ownership

31.8% of Alphatec shares are held by institutional investors. Comparatively, 11.4% of Pulse Biosciences shares are held by institutional investors. 28.2% of Alphatec shares are held by insiders. Comparatively, 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Alphatec and Pulse Biosciences' net margins, return on equity and return on assets.

Volatility and Risk

Alphatec has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Summary

Pulse Biosciences beats Alphatec on 7 of the 12 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Luminex and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Luminex has higher revenue and earnings than Pulse Biosciences. Luminex is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Luminex and Pulse Biosciences, as provided by MarketBeat.

Luminex presently has a consensus target price of $38.00, suggesting a potential upside of 15.33%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Luminex.

Insider & Institutional Ownership

88.1% of Luminex shares are held by institutional investors. Comparatively, 11.4% of Pulse Biosciences shares are held by institutional investors. 9.4% of Luminex shares are held by insiders. Comparatively, 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Luminex and Pulse Biosciences' net margins, return on equity and return on assets.

Risk & Volatility

Luminex has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500.

Summary

Luminex beats Pulse Biosciences on 8 of the 12 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Pulmonx and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Pulmonx has higher revenue and earnings than Pulse Biosciences.

Analyst Ratings

This is a summary of recent recommendations for Pulmonx and Pulse Biosciences, as provided by MarketBeat.

Pulmonx presently has a consensus target price of $58.00, suggesting a potential upside of 33.39%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Pulmonx.

Insider & Institutional Ownership

11.4% of Pulse Biosciences shares are held by institutional investors. 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Pulmonx and Pulse Biosciences' net margins, return on equity and return on assets.

Summary

Pulmonx beats Pulse Biosciences on 5 of the 9 factors compared between the two stocks.